Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AMLODIPINE vs RIBOCICLIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

AMLODIPINE vs RIBOCICLIB: Safety Overview

Metric AMLODIPINE RIBOCICLIB
Total FAERS Reports 64,924 27,997
Deaths Reported 10,161 4,501
Death Rate 15.7% 16.1%
Hospitalizations 26,787 6,700
Average Patient Age 62.8 yrs 60.2 yrs
% Female Patients 57.0% 99.0%
FDA Approval Date Apr 12, 2011 Mar 13, 2017
Manufacturer Teva Pharmaceuticals USA, Inc. Novartis Pharmaceuticals Corporation
Route ORAL ORAL
Marketing Status Prescription Prescription